Cytosine arabinoside (ARA-C)

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
20011
A randomized trial of BEAM + PBSCT versus single agent high-dose therapy followed by BEAM + PBSCT in patients with relapsed Hodgkin's disease (HD-R2 protocol).
06013
Idarubicin and Ara-C in combination with Gemtuzumab-Ozogamycin (IAGO) for untreated patients, with or without an HLA identical sibling, with high risk MDS or AML developing after a preceding period with MDS during 6 months duration : a phase II study.
06012
Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 - 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC - LG and the GIMEMA-ALWP
06991
The value of high dose versus standard dose Ara-c during induction and IL-2 after intensive consolidation/autologous stem cell transplantation in patients (age 15-60 yrs) with acute myelogenous leukemia. A randomized phase III trial of the EORTC and GIMEMA Leukemia Cooperative Groups (AML-12).
58051
International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia
58951
The value of 1) Dexamethasone vs prednisolone during induction 2) of prolonged versus conventional duration of L-Asparaginase therapy during consolidation and late intensification, in acute lymphoblastics leukemia and lymphoblastic non-Hodgkin lymphoma of childhood. A Randomised phase III study.
58953
Phase II Study of Fludarabine + Idarubicine + Aracytine in Refractory or Relapsed Acute Lymphocytic Leukemia in Children.

Back to Protocol section